1. Home
  2. PEW vs CRDF Comparison

PEW vs CRDF Comparison

Compare PEW & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PEW
  • CRDF
  • Stock Information
  • Founded
  • PEW 2007
  • CRDF 1999
  • Country
  • PEW United States
  • CRDF United States
  • Employees
  • PEW N/A
  • CRDF N/A
  • Industry
  • PEW Other Specialty Stores
  • CRDF Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PEW Consumer Discretionary
  • CRDF Health Care
  • Exchange
  • PEW Nasdaq
  • CRDF Nasdaq
  • Market Cap
  • PEW 156.5M
  • CRDF 144.4M
  • IPO Year
  • PEW N/A
  • CRDF N/A
  • Fundamental
  • Price
  • PEW $5.06
  • CRDF $2.18
  • Analyst Decision
  • PEW Strong Buy
  • CRDF Strong Buy
  • Analyst Count
  • PEW 1
  • CRDF 5
  • Target Price
  • PEW $8.25
  • CRDF $11.10
  • AVG Volume (30 Days)
  • PEW 1.2M
  • CRDF 811.0K
  • Earning Date
  • PEW 11-14-2025
  • CRDF 11-06-2025
  • Dividend Yield
  • PEW N/A
  • CRDF N/A
  • EPS Growth
  • PEW N/A
  • CRDF N/A
  • EPS
  • PEW N/A
  • CRDF N/A
  • Revenue
  • PEW $90,690,000.00
  • CRDF $545,000.00
  • Revenue This Year
  • PEW N/A
  • CRDF N/A
  • Revenue Next Year
  • PEW N/A
  • CRDF N/A
  • P/E Ratio
  • PEW $45.90
  • CRDF N/A
  • Revenue Growth
  • PEW N/A
  • CRDF N/A
  • 52 Week Low
  • PEW $4.34
  • CRDF $1.90
  • 52 Week High
  • PEW $21.40
  • CRDF $5.64
  • Technical
  • Relative Strength Index (RSI)
  • PEW 42.34
  • CRDF 51.17
  • Support Level
  • PEW $4.34
  • CRDF $1.99
  • Resistance Level
  • PEW $5.82
  • CRDF $2.13
  • Average True Range (ATR)
  • PEW 0.33
  • CRDF 0.10
  • MACD
  • PEW 0.02
  • CRDF 0.04
  • Stochastic Oscillator
  • PEW 49.32
  • CRDF 72.13

About PEW GrabAGun Digital Holdings Inc. Common Stock

GrabAGun Digital Holdings Inc is a multi-brand eCommerce retailer of firearms, ammunition, and related accessories.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Share on Social Networks: